PARP inhibitors in non-ovarian gynecologic cancers

• Published in: Therapeutic advances in medical oncology Vol. 16; p. 17588359241255174
• Main Authors: Fernandes, Italo, Chehade, Rania, MacKay, Helen
• Format: Journal Article
• Language: English
• Published: England SAGE Publications 01-01-2024; SAGE Publishing
• Subjects: PARP Inhibitors in Gynecologic Cancers: What’s Next?; clinical trials; predictive biomarker; homologous recombination deficiency; PARP inhibitor; novel therapies
• ISSN: 1758-8340; 1758-8359
• DOI: 10.1177/17588359241255174

Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) have transformed the treatment of ovarian cancer, particularly benefiting patients whose tumors harbor genomic events that result in impaired homologous recombination (HR) repair. The use of PARPi over recent years has expanded to include subpopulations of patients with breast, pancreatic, and prostate cancers. Their potential to benefit patients with non-ovarian gynecologic cancers is being recognized. This review examines the underlying biological rationale for exploring PARPi in non-ovarian gynecologic cancers. We consider the clinical data and place this in the context of the current treatment landscape. We review the development of PARPi strategies for treating patients with endometrial, cervical, uterine leiomyosarcoma, and vulvar cancers. Furthermore, we discuss future directions and the importance of understanding HR deficiency in the context of each cancer type.